NCT03363243 is a NA clinical trial of STOP Therapy Treatment group in Opioid-use Disorder, sponsored by University of Colorado, Denver.

Who is sponsoring NCT03363243?

NCT03363243 is sponsored by University of Colorado, Denver.

What drugs are being tested in NCT03363243?

Interventions in NCT03363243: STOP Therapy Treatment group, Treatment as usual (TAU) group.

What condition does NCT03363243 study?

NCT03363243 studies Opioid-use Disorder, Chronic Pain.

Is NCT03363243 still recruiting?

NCT03363243 is currently completed. Last updated 27 March 2025.

Last reviewed 2025-03-27 · How we verify

NCT03363243

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Advancing STOP: Self-regulation Therapy for Opioid Addiction and Pain

Completed NA Last updated 27 March 2025

What this trial tests

NA trial testing STOP Therapy Treatment group in Opioid-use Disorder in 52 participants. Completed in 30 June 2024.

Timeline

1 March 2018

Primary endpoint
21 April 2022

30 June 2024

Quick facts

Lead sponsor	University of Colorado, Denver
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	52
Start date	1 March 2018
Primary completion	21 April 2022
Estimated completion	30 June 2024
Sites	1 location across United States

Drugs / interventions tested

STOP Therapy Treatment group
Treatment as usual (TAU) group

Conditions studied

Opioid-use Disorder — all drugs for Opioid-use Disorder →
Chronic Pain — all drugs for Chronic Pain →

Sponsor

University of Colorado, Denver

Who can join

Adults 18 to 65, any sex, with Opioid-use Disorder or Chronic Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The public health relevance of this proposed project is substantial given the current opioid abuse epidemic as identified by the Centers for Disease Control (CDC). This study finalizes and tests a new psychotherapy treatment that is designed to treat chronic pain and opioid addiction at the same time in a format that could be easily used in a community addiction treatment setting. Final products of the study will yield an integrated STOP (Self-regulation/Cognitive-behavioral therapy (CBT) Therapy for Opioid addiction and Pain) manual guided protocol, patient workbook, and therapist training protocol.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Developing a novel treatment for patients with chronic pain and Opioid User Disorder.
Wachholtz A, Robinson D, Epstein E. · · 2022 · cited 13× · PMID 35525964 · DOI 10.1186/s13011-022-00464-4
Lessons Learned: Developing a Better Treatment for Patients With Chronic Pain and Opioid User Disorder
Wachholtz A, Robinson D, Epstein E. · · 2021 · DOI 10.21203/rs.3.rs-936608/v1

Verify or expand the search:

Other recruiting trials for Opioid-use Disorder

Currently open trials in the same condition.

NCT04783558 — Effective Caregiving for Neonatal Abstinence Syndrome: Testing an Instructional Mobile Technology Platform for High-Risk · NA · active not recruiting
NCT05011266 — Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder · Phase 2, PHASE3 · recruiting
NCT05039554 — Randomized Trial of ACT and a Care Management App in Primary Care-based Buprenorphine Treatment · NA · recruiting
NCT05033028 — Smartphones for Opiate Addiction Recovery · Phase 3 · recruiting
NCT04738825 — Promoting HIV Risk Reduction Among People Who Inject Drugs: A Stepped Care Approach Using Contingency Management With Pr · NA · recruiting

Other University of Colorado, Denver trials

Trials by the same sponsor.

NCT07292285 — The Surveillance Nonoperative Watch & Wait (SNOWW) Rectal Cancer Trial. · not yet recruiting
NCT07021937 — Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity · Phase 3 · not yet recruiting
NCT07453732 — Banana Leaves as a Wound Dressing for Partial Thickness Second Degree Burns in Adult Patients. · NA · not yet recruiting
NCT07038278 — 5-AminoLevulinic Acid Aided Resection Margins in Sarcoma · EARLY_PHASE1 · not yet recruiting
NCT07279558 — Cannabidiol and Alcohol Use Disorder Phenotypes · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03363243 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Colorado, Denver
Last refreshed: 27 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03363243.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing